Genomic Health to present study results of Oncotype DX multi-gene expression test

Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from two studies at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, taking place October 8 through October 10 at the San Francisco Marriott in San Francisco, California. Both studies analyze Oncotype DX®, the company's multi-gene expression test that physicians use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.

Presentation details are as follows (all times are Pacific Daylight Time): - Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT) Poster Board #A15 Poster presentation: "Biopsy Cavities in Breast Cancer Specimens: Impact on Gene Expression Profiles and Recurrence Risk Assessment" Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco Location: Golden Gate Hall - Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT) Poster Board #A19 Poster Presentation: "A Study of the Oncotype DX(R) Recurrence Score(R) as a Prognostic Factor in Early Stage Breast Cancer in the Japanese Population" Presenter: Masakazu Toi, M.D., Ph.D, Department of Surgery, Graduate School of Medicine, Kyoto University Location: Golden Gate Hall